

Robust volume growth momentum continues...

Varun Beverages (VBL) reported 49.2% YoY growth in revenues to ₹ 1739.7 led by 60.4% overall volume growth on the back of acquisition of south and west sub-territories from PepsiCo. India organic volume growth of 17.5% was led by good performance in underpenetrated territories acquired in the last two years. International volume growth of 27% was on account of double digit growth in Morocco, Zimbabwe, Nepal and Sri Lanka. EBITDA increased 54.2% to ₹ 325.7 crore with 60 bps improvement in operating margins to 18.7% on account of benign raw material cost & operating leverage in the business. Led by strong operating profit growth, net profit increased 83.4% to ₹ 81.1 crore.

Healthy business growth in domestic, international markets

VBL's domestic sales volumes in Q3CY19 were at 98 million (mn) cases with organic growth of 17.5% YoY on account of increase in distribution in under penetrated rural regions. Its international volumes were at 26 mn with organic growth of 27% driven by double digit growth in all overseas operations except Zambia. Volume contribution from acquired territories were at 32 mn cases. With the recent acquisition, capacity utilisation for VBL was at 60% against erstwhile 70%, which gives tremendous scope for increasing utilisation levels further without going for any expansion in the near term. We expect revenue CAGR of 20.2% in CY18-21E.

Operating leverage, benign material costs aid margins

EBITDA margins increased 60 bps to 18.7% in Q3CY19 driven by operating leverage, improving product mix, lower PET prices in India & lower sugar prices in Zimbabwe. With the commencement of the Pathankot facility in June, Tropicana juices revenue would start reflecting by next quarter, growing its profitability margin. As non-carbonated beverage (NCB) enjoy highest realisations and are less seasonal than carbonates, we believe new launches in these categories augur well for long-term growth prospects and will reduce seasonality, boost profitability, augment return ratios. Also, with acquired south & west sub-territories having higher contribution of water than the existing territories and on account of full impact of commissioning of a second line of water in Morocco, packaged water would help ease cyclicalities, going forward. We expect NCD & bottled water segments to clock revenue CAGR of 33.7% & 20.6% in CY18-21E, respectively.

Valuation & Outlook

We believe strong organic growth in the last couple of quarters allays concerns regarding the soft drink industry in India. Additionally, the company's focus on healthier options would help drive incremental volumes and margins. As volume growth picks up in new territories and the company participates in the manufacturing segment of Tropicana, we expect revenue & earnings CAGR of 20.2% & 28.9% in CY18-21E, respectively. We value VBL at 35x CY21E earnings. We upgrade our recommendation to **BUY** with a revised target price of ₹ 805/share.

Key Financial Summary

Key Financials	CY17	CY18	CY19E	CY20E	CY21E	CAGR (CY18-21E)
Net Sales	4003.5	5105.3	7024.6	7925.9	8868.5	20.2%
EBITDA	835.9	1006.6	1300.0	1410.8	1586.9	16.4%
EBITDA Margin %	20.9	19.7	18.5	17.8	17.9	
Net Profit	214.0	299.9	410.3	498.5	642.3	28.9%
EPS (₹)	11.72	16.42	14.45	17.56	22.62	
P/E	59.7	42.6	48.5	39.9	30.9	
RoNW %	12.1	15.0	12.0	13.1	14.9	
RoCE (%)	12.7	14.2	14.1	15.3	17.7	

Source: Company, ICICI Direct Research



Particulars

Particulars (₹ crore)	Amount
Market Capitalization	19877
Total Debt (CY18)	2,600.0
Cash & Investments (CY18)	43.0
EV	21,827.7
52 week H/L (₹)	727 / 456
Equity capital	273.9
Face value	10.0

Key Highlights

- Total sales volumes rose to 124 mn cases from 78 mn cases in Q3CY19
- India sales volume were at 98 mn cases (32 mn cases from acquired South & West regions) and international sales volume were at 26 mn cases
- CSD constituted 69%, juices 6% and packaged drinking water 25% of total sales volumes in Q3CY19
- Changed from HOLD to BUY with revised target price of ₹ 805/share

Research Analyst

Sanjay Manyal
sanjay.manyal@icicisecurities.com

Kapil Jagasia, CFA
kapil.jagasia@icicisecurities.com

Exhibit 1: Variance Analysis

Particulars (₹ crore)	Q3CY19	Q3CY18	YoY (%)	Q2CY19	QoQ (%)	Comments
Net Sales	1,739.7	1,165.7	49.2	2,810.5	-38.1	Net sales witnessed growth of 49.2% led by 60.4% overall volume growth well supported by India organic volume growth of 17.5% and international volume growth of 27%
Raw Material Expenses	747.2	526.7	41.9	1,329.5	-43.8	Gross margins expanded 223 bps on account of lower PET prices in India and lower sugar prices in Zimbabwe territory
Employee Expenses	229.6	148.6	54.5	199.2	15.3	Employee expenses were up 54.% due to acquisition of south & west region sub-territories
Other operating Expenses	437.3	279.2	56.6	493.9	-11.5	
EBITDA	325.7	211.2	54.2	787.9	-58.7	
EBITDA Margin (%)	18.7	18.1	60 bps	28.0	-931 bps	Operating margins improved 60 bps on account of operating leverage in business
Depreciation	127.3	99.9	27.5	125.4	1.5	Depreciation increased 27.5% on account of capitalisation of Pathankot plant and consolidation of south and west India sub-territories
Interest	86.7	47.2	83.9	84.8	2.3	Finance cost increased 83.9% as purchase consideration for acquisition of south and west India sub-territories was funded through debt
Other Income	1.8	0.6	214.7	3.3	-46.0	
PBT	113.4	64.8	74.9	581.0	-80.5	
Exceptional Items	0.0	-0.1		0.0		
Tax Outgo	34.5	21.2	62.8	177.3	-80.5	
PAT	81.1	44.2	83.4	405.0	-80.0	Net profit increased 83.4% positively impacted by increase in sales volumes

Source: Company, ICICI Direct Research

Exhibit 2: Change in estimates

(₹ Crore)	CY19E			CY20E			CY21E			Comments
	Old	New	% Change	Old	New	% Change	Old	New	% Change	
Net Sales	7,257.0	7,024.6	-3.2	8,182.9	7,925.9	-3.1	9,150.3	8,868.5	-3.1	We slightly revise revenue estimates
EBITDA	1358.4	1300.0	-4.3	1,536.9	1,410.8	-8.2	1,680.6	1,586.9	-5.6	
EBITDA Margin(%)	18.7	18.5	-21 bps	18.8	17.8	-98 bps	18.4	17.9	-47 bps	
PAT	427.3	410.3	-4.0	505.6	498.5	-1.4	592.8	642.3	8.3	We revise upward CY21E PAT estimates as acquired South & West sub-territories have consolidated
EPS (₹)	15.05	14.45	-4.0	17.80	17.56	-1.4	20.9	22.62	8.4	

Source: Company, ICICI Direct Research

Exhibit 3: Assumptions

Particulars (₹ crore)	Current					Earlier			Comments
	CY17	CY18	CY19E	CY20E	CY21E	CY19E	CY20E	CY21E	
Carbonated Products	124.9	145.9	220.3	242.4	261.8	220.3	242.4	261.8	No change in estimates
% Growth	-1.3	16.8	51.0	10.0	8.0	51.0	10.0	8.0	
Non Carbonated Products	7.9	12.5	16.9	21.1	25.3	16.9	21.1	25.3	
% growth	-11.1	57.1	35.0	25.0	20.0	35.0	25.0	20.0	
Drinking Water	25.6	34.6	45.0	51.8	59.0	45.0	51.8	59.0	
% growth	21.4	35.6	30.0	15.0	14.0	30.0	15.0	14.0	
Raw Material Cost									
Sugar	616.6	698.4	1,086.0	1,206.2	1,324.7	1,086.0	1,206.2	1,324.7	
% of sales	13.4	14.2	15.1	14.8	14.5	14.7	14.3	14.0	
cost/kg (₹)	38.9	37.0	36.6	36.6	38.5	36.6	36.6	38.5	


Source: Company, ICICI Direct Research

Conference Call Highlights

- Revenues increased 49.2% YoY to ₹ 1739.7 crore led by 60.4% overall volume growth well supported by India organic volume growth of 17.5% led by good performance in underpenetrated territories acquired in last two years and international organic volume growth of 27% on account of double digit growth in Morocco, Zimbabwe, Nepal and Sri Lanka. Realisation per case has come down by ~7% essentially on account of a change in product mix in India post consolidation of south and west sub-territories, introduction of water in Morocco and lower sales realisation in Zimbabwe
- Total sales volumes rose to 124 million (mn) cases during the quarter from 78 mn cases in Q3CY18. India sales volume were at 98 mn cases (32 mn cases from acquired south & west regions) while international sales volume was at 26 mn cases. International volumes were higher on account of the full impact of the commissioning of a second line of water unit in Morocco and double digit growth in all international territories except de-growth in Zambia
- Carbonated soft drink (CSD) constituted 69%, juice 6% and packaged drinking water 25% of total sales volumes in Q3CY19
- Gross margins expanded 223 bps YoY to 57.1% on account of lower PET prices in India and lower sugar prices in Zimbabwe territory
- EBITDA increased 54.2% to ₹ 325.7 crore translating into blended EBITDA margins of 18.7% (up 60 bps YoY). The margin improvement was driven by operating leverage in the business
- Led by strong operating profit growth, net profit increased 83.4% to ₹ 81.1 crore, positively impacted by increase in sales volumes
- Gross debt was at ₹ 2900 crore in Q3CY19 against ₹ 3730 crore as on Q2CY19 helped by ₹ 900 crore raised via QIP during the quarter. D/E ratio was at 0.9x as on Q3CY19. Capex was at ₹ 2200 crore for CY19
- The company has no plans of setting up a greenfield plant in future. Any expansion would be met through brownfield expansion
- The company is still evaluating a shift towards lower corporate tax regime and shall take a decision on it in Q4CY19. It uses MAT credit and wants to use the same, going forward
- The company has concluded acquisition of two production facilities - one in Dharwad, Karnataka and second at Tirunelveli, Tamil Nadu for a total consideration of ₹ 95 crore
- During the quarter, VBL acquired 20% stake in Lunarmech Technologies Pvt Ltd for ₹ 15 crore taking its stake in the company to 55%
- As per the management, realisation should increase driven by manufacturing of Tropicana juices and the recently launched dairy-based beverages
- Organic volume growth in CSD, water & juices was at 19.2%, 13.3% & 11.6%, respectively
- On an annualised basis, 135 mn cases were sold by Pepsi when they owned south and west territories. VBL expects around 60% of it to flow in this year
- During the quarter, VBL launched three value added dairy beverages – Belgian Chocolate, Cold Coffee and Mango shake at ₹ 30 for 200 ml PET bottle


Key Metrics

Exhibit 4: Revenue growth trend




Source: Company, ICICI Direct Research

Exhibit 5: Volume growth to drive revenue




Source: Company, ICICI Direct Research

Exhibit 6: Segment wise volume contribution (%)




Source: Company, ICICI Direct Research

Exhibit 7: Segment wise value contribution (%)




Source: Company, ICICI Direct Research

Exhibit 8: Raw material to sales & EBITDA margins (%)




Source: Company, ICICI Direct Research

Exhibit 9: EBITDA (₹ crore) & EBITDA growth (%)




Source: Company, ICICI Direct Research

Exhibit 10: Earnings to witness CAGR of 28.9% (CY18-21E)




Source: Company, ICICI Direct Research

Exhibit 11: Return ratios to improve (%)




Source: Company, ICICI Direct Research

Exhibit 12: Brand wise volume contribution (%)



Source: Company, ICICI Direct Research

Exhibit 13: Geography wise revenue break up (%)




Source: Company, ICICI Direct Research

Exhibit 14: Valuation

	Sales	Growth	EPS	Growth	PE	EV/EBITDA	RoNW	RoCE
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)
CY18	5105.3	27.5	16.4	40.1	42.6	22.0	15.0	14.2
CY19E	7024.6	37.6	14.4	-12.0	48.5	17.1	12.0	14.1
CY20E	7925.9	12.8	17.6	21.5	39.9	15.5	13.1	15.3
CY21E	8868.5	11.9	22.6	28.8	30.9	13.5	14.9	17.7

Source: Company, ICICI Direct Research

Exhibit 15: Recommendation History vs. Consensus


Source: Bloomberg, Company, ICICI Direct Research

Exhibit 16: Top 10 Shareholders

Rank	Name	Latest Filing Date	% O/S	Position (m)	Change (m)
1	RJ Corp Ltd.	30-Sep-19	28.07	81.0	-2.7
2	Jaipuria (Ravi Kant)	30-Jun-19	20.36	58.8	0.0
3	Jaipuria (Ravi Kant & Sons) HUF	30-Sep-19	19.91	57.5	57.5
4	Jaipuria (Varun)	30-Sep-19	17.55	50.7	0.0
5	Capital Research Global Investors	30-Sep-19	4.30	12.4	0.0
6	Jaipuria (Devayani)	30-Sep-19	2.81	8.1	0.0
7	Reliance Nippon Life Asset Management Limited	30-Sep-19	2.66	7.7	0.2
8	Sundaram Asset Management Company Limited	30-Sep-19	2.08	6.0	1.3
9	Tata Asset Management Limited	30-Sep-19	1.98	5.7	0.0
10	Norges Bank Investment Management (NBIM)	30-Sep-19	1.94	5.6	5.6

Source: Reuters, ICICI Direct Research

Exhibit 17: Recent Activity

Buys			Sells		
Investor name	Value	Shares	Investor name	Value	Shares
Jaipuria (Ravi Kant & Sons) HUF	507.85m	57.48m	RJ Corp Ltd.	-23.85m	-2.70m
Norges Bank Investment Management (NBIM)	49.35m	5.59m	Marina IV (Singapore) Pte. Ltd.	-7.59m	-0.83m
Stichting Depository APG Emerging Markets Equity Pool	15.85m	1.79m	Nordea Funds Oy	-1.81m	-0.20m
Capital International Investors	15.64m	1.77m	Capital International, Inc.	-1.16m	-0.13m
Sundaram Asset Management Company Limited	11.58m	1.31m	Agarwal (Kapil)	-0.90m	-0.10m

Source: Reuters, ICICI Direct Research

Exhibit 18: Shareholding Pattern

(in %)	Sep-18	Dec-18	Mar-19	Jun-19	Sep-19
Promoter	73.6	73.6	73.6	73.6	68.4
FII	12.7	13.0	13.5	14.2	19.2
DII	5.5	5.7	6.4	6.6	6.4
Others	8.2	7.7	6.5	5.6	6.0

Source: Company, ICICI Direct Research

Financial summary

Exhibit 19: Profit and loss statement ₹ crore				
	CY18	CY19E	CY20E	CY21E
Total operating income	5105.3	7024.6	7925.9	8868.5
Growth (%)	27.5	37.6	12.8	11.9
Raw Material Expenses	2244.1	3164.5	3584.4	4000.9
Employee Expenses	583.0	843.0	990.7	1108.6
Marketing Expenses	112.7	107.6	122.5	137.1
Other expenses	1159.0	1609.6	1817.4	2035.1
Total Operating Expenditure	4098.7	5724.6	6515.0	7281.6
EBITDA	1,006.6	1,300.0	1,410.8	1,586.9
Growth (%)	20.4	29.1	8.5	12.5
Depreciation	385.1	478.1	502.9	527.7
Interest	212.6	291.9	259.3	215.3
Other Income	21.8	33.5	36.9	40.5
PBT	430.8	563.5	685.5	884.4
Total Tax	133.9	157.8	191.9	247.6
Minority interest	0.0	0.0	0.0	0.0
Profit from Associates	3.0	4.5	5.0	5.5
PAT	299.9	410.3	498.5	642.3
Growth (%)	40.1	36.8	21.5	28.8
EPS (₹)	16.4	14.4	17.6	22.6

Source: Company, ICICI Direct Research

Exhibit 20: Cash flow statement ₹ crore				
(Year-end March)	CY18	CY19E	CY20E	CY21E
Profit After Tax	664.8	697.7	752.9	852.1
Add: Depreciation	385.1	478.1	502.9	527.7
(Inc)/dec in Current Assets	-278.0	133.7	-381.4	-154.0
Inc/(dec) in CL and Provisions	227.9	-194.4	150.2	9.5
CF from operating activities	999.8	1,114.9	1,024.6	1,235.4
(Inc)/dec in Investments	0.0	0.0	0.0	0.0
(Inc)/dec in LT loans & advances	0.0	0.0	0.0	0.0
(Inc)/dec in Fixed Assets	-857.9	-1,844.9	-427.6	-428.9
Others	-15.5	0.0	0.0	0.0
CF from investing activities	-873.4	-1,844.9	-427.6	-428.9
Issue/(Buy back) of Equity	0.7	900.0	0.0	0.0
Inc/(dec) in loan funds	756.6	150.0	-300.0	-500.0
Dividend paid & dividend tax	-51.1	0.0	-99.7	-128.5
Others	-488.6	-291.9	-259.3	-215.3
CF from financing activities	-84.4	866.9	-643.1	-827.0
Net Cash flow	42.0	136.9	-46.1	-20.6
Opening Cash	64.9	93.5	198.3	152.2
Other Bank balance	50.5	0.0	0.0	0.0
Closing Cash	93.5	198.3	152.2	131.6

Source: Company, ICICI Direct Research

Exhibit 21: Balance sheet ₹ crore				
(Year-end March)	CY18	CY19E	CY20E	CY21E
Liabilities				
Equity Capital	182.6	284.0	284.0	284.0
Reserve and Surplus	1815.9	3126.2	3525.0	4038.8
Total Shareholders funds	1998.5	3410.1	3808.9	4322.8
LT Borrowings & Provisions	1980.1	2180.1	1980.1	1680.1
Deferred Tax Liability	192.2	201.8	211.9	222.5
Total Liabilities	4290.5	5909.6	6124.4	6355.0
Assets				
Gross Block	5,558.2	7,710.6	8,110.6	8,510.6
Less: Acc Depreciation	1,698.0	2,176.1	2,678.9	3,206.6
Net Block	3,860.2	5,534.5	5,431.6	5,304.0
Capital WIP	352.4	50.0	50.0	50.0
Net Intangible Assets	524.9	551.1	578.7	607.6
Non-current Investments	0.8	0.8	0.8	0.8
Goodwill	1.9	1.9	1.9	1.9
Current Assets				
Inventory	578.4	682.9	880.7	985.4
Debtors	128.0	156.1	176.1	197.1
Loans and Advances	1.6	58.5	220.2	246.3
Other Current Assets	198.4	15.6	17.6	19.7
Cash	93.5	198.3	152.2	131.6
Deferred Tax Assets	33.4	33.4	33.4	33.4
Current Liabilities				
Creditors	316.8	487.8	550.4	591.2
Provisions	16.0	58.5	66.0	73.9
Short term debt & other CL	1,375.6	913.0	888.1	643.5
Application of Funds	4,290.5	5,909.6	6,124.4	6,355.0

Source: Company, ICICI Direct Research

Exhibit 22: Key ratios ₹ crore				
(Year-end March)	CY18	CY19E	CY20E	CY21E
Per share data (₹)				
EPS	16.4	14.4	17.6	22.6
Cash EPS	37.5	31.3	35.3	41.2
BV	109.4	120.1	134.1	152.2
DPS	0.0	0.0	3.5	4.5
Cash Per Share	93.0	76.6	94.3	112.9
Operating Ratios (%)				
EBITDA Margin	19.7	18.5	17.8	17.9
PBT / Total Operating income	8.4	8.0	8.6	10.0
PAT Margin	5.9	5.8	6.3	7.2
Inventory days	41.4	35.5	40.6	40.6
Debtor days	9.2	8.1	8.1	8.1
Creditor days	22.6	25.3	25.3	24.3
Return Ratios (%)				
RoE	15.0	12.0	13.1	14.9
RoCE	14.2	14.1	15.3	17.7
Valuation Ratios (x)				
P/E	42.6	48.5	39.9	30.9
EV / EBITDA	22.0	17.1	15.5	13.5
EV / Net Sales	4.3	3.2	2.8	2.4
Market Cap / Sales	3.9	2.8	2.5	2.2
Price to Book Value	6.4	5.8	5.2	4.6
Solvency Ratios				
Debt/EBITDA	2.3	1.9	1.6	1.1
Debt / Equity	1.2	0.7	0.6	0.4
Current Ratio	0.5	0.8	1.0	1.1
Quick Ratio	0.1	0.2	0.3	0.3

Source: Company, ICICI Direct Research

Exhibit 23: ICICI Direct coverage universe (FMCG)

Sector / Company	CMP	TP	M Cap	EPS (₹)			P/E (x)			Price/Sales (x)			RoCE (%)			RoE (%)			
	(₹)	(₹) Rating		(₹ Cr)	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E
Colgate (COLPAL)	1,520	1,400	Hold	37,806	28.5	34.0	37.1	53.3	44.7	41.0	8.5	7.9	7.3	70.7	73.5	69.4	52.2	57.2	53.9
Dabur India (DABIND)	465	520	Buy	78,164	8.2	9.3	10.3	56.8	50.1	45.2	9.2	8.4	7.6	29.6	29.9	30.0	25.7	26.8	26.7
GSK CH (GLACON)	9,170	8,780	Hold	35,327	233.7	272.5	N.A.	39.2	33.7	N.A.	7.4	6.8	N.A.	36.1	32.6	N.A.	24.0	24.8	N.A.
Hindustan Unilever (HINLEV)	2,160	2,075	Hold	440,640	27.9	34.7	40.7	77.3	62.2	53.1	11.7	10.5	9.2	85.3	103.9	111.2	80.9	89.7	96.5
ITC Limited (ITC)	260	320	Buy	306,114	10.3	12.3	13.8	25.3	21.1	18.9	6.9	6.4	5.9	30.8	30.9	30.9	21.5	23.8	23.8
Jyothy Lab (JYOLAB)	177	185	Hold	6,363	5.3	5.9	6.5	33.3	30.0	27.2	3.6	3.3	3.0	28.6	28.5	30.6	22.6	22.4	23.5
Marico (MARLIM)	365	410	Hold	50,705	8.8	8.5	9.3	41.5	43.2	39.2	6.9	6.4	5.9	38.0	41.4	43.5	31.6	34.1	35.7
Nestle (NESIND)	14,700	14,575	Hold	129,685	166.7	223.9	267.9	88.2	65.7	54.9	11.6	10.3	9.1	42.9	43.0	44.6	45.6	48.8	47.7
Tata Global Bev (TATGLO)	302	350	Buy	18,933	7.2	9.2	10.1	41.7	32.8	29.8	2.6	2.5	2.3	8.4	10.2	10.6	6.5	8.4	8.7
VST Industries (VSTIND)	3,920	4,600	Buy	5,714	146.9	193.1	210.5	26.7	20.3	18.6	5.2	4.5	4.2	51.4	50.7	48.6	34.2	38.1	36.5
Varun Beverage (VARBEV)	650	805	Buy	19,877	11.7	16.4	14.4	55.4	39.6	45.0	5.0	3.9	2.8	12.7	14.2	14.1	12.1	15.0	12.0

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Sanjay Manyal, MBA (Finance) and Kapil Jagasia, CFA, MBA (Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.